Le Lézard
Classified in: Covid-19 virus

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in LifeStance Health Group, Inc. with Losses of $100,000 to Contact the Firm


LOS ANGELES, CA / ACCESSWIRE / August 16, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against LifeStance Health Group, Inc. ("LifeStance" or "the Company") (NASDAQ:LFST) for violations of the federal securities laws.

https://storage.googleapis.com/accesswire/logos/3060.png

Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on June 10, 2021 (the "IPO"), are encouraged to contact the firm before October 11, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. LifeStance suffered from a decrease in virtual visits by clients as COVID-19 lockdowns were ending, negatively impacting its out-patient/virtual revenue growth. The Company's operating expenses significantly increased as the number of in-person visits were increasing. The Company lost a significant number of physicians to burn-out, dropping its retention rate below the 87% retention rate touted in the IPO materials. Based on these facts, the Company's public statements were false and materially misleading throughout the IPO period. When the market learned the truth about LifeStance, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE: The Schall Law Firm



View source version on accesswire.com:
https://www.accesswire.com/712065/INVESTOR-ACTION-ALERT-The-Schall-Law-Firm-Encourages-Investors-in-LifeStance-Health-Group-Inc-with-Losses-of-100000-to-Contact-the-Firm


These press releases may also interest you

at 08:05
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:00
The "Global Men's Health and Wellness Market: Analysis By Type, By Distribution Channel, By Region Size & Forecast with Impact Analysis of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering. In 2023, the...

at 08:00
Citius Pharmaceuticals Inc. ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive...

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:40
NuRAN Wireless Inc. ("NuRAN" or the "Company") , a leading supplier of mobile and broadband wireless infrastructure solutions, is pleased to announce the execution of a two-year term loan facility agreement (the "Loan...

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...



News published on and distributed by: